Neurotrophic signalling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-25. Numbers and descriptions here follow the published literature rather than marketing material.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥ 95 % of peak area by HPLC | Some suppliers quote 98 % or higher |
| Identity confirmation | Mass spectrometry (electrospray or MALDI) | Observed mass is compared with the calculated mass |
| Common analytical method | Reversed-phase HPLC on a C18 column | Acetonitrile and water gradients with trifluoroacetic acid |
| Primary degradation route | Oxidation of the methionine residue | Yields a sulfoxide that separates cleanly on chromatography |
| Storage of dissolved material | Aliquoted and frozen at −20 °C or below | Single-use aliquots avoid repeated temperature cycling |
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Xenon-135 (135Xe) is an unstable isotope of xenon with a half-life of 9.14 hours, decaying to long-lived caesium-135. 135Xe is a fission product and it is the most powerful known neutron-absorbing nuclear poison (2 million barns; up to 3 million barns under reactor conditions), with a significant effect on nuclear reactor operation. The yield of xenon-135 from fission is about 6.6% (uranium) or 7.4% (plutonium), the great majority from iodine-135. It is normal for fission products to be formed in such a chain of decays.
=== Increases in federal funding === On June 17, 1971, Nixon held a press conference in which he announced, "America's public enemy number one in the United States is drug abuse." He continued, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive." In the speech, Nixon called for Congress to approve the allocation of $150 million in new funding to the "treatment and prevention of drug abuse." According to the Bureau of Labor Statistics, that is now the equivalent of just under $966 million.
(2026) reconstruct the demographic history of late Neanderthals on the basis of data from mitochondrial DNA, reporting evidence indicating that nearly all late Neanderthals from Europe belonged to a single mitochondrial DNA lineage, likely as a result of expansion across Europe from a refugium in southwestern France, and evidence of rapid decline in the effective population size of late Neanderthals shortly before their extinction; Sánchez Goñi & d'Errico (2026) link the presence of the refugium in southwestern France to the climatic configuration affecting western Europe 76,000 to 68,000 years ago. Bossoms Mesa et al. (2026) reconstruct the genetic diversity of late Neanderthals from Belgium and France, finding no evidence of mating among close relatives or genetic deterioration prior to Neanderthal extinction. Yousefi et al. (2026) study changes in suitability and connectivity of Neanderthal habitat through time, and find no evidence of habitat fragmentation caused by climate changes before Neanderthal extinction. Baykara et al. (2026) report evidence of sequential occupation of the Üçağızlı II Cave (Turkey) by Neanderthals and modern humans, and evidence of cultural continuity between members of the two human lineages occupying the site. Schoenemann et al. (2026) interpret differences in brain anatomy of Neanderthals and modern humans as falling within the range of differences between modern human populations, and find no evidence of significang cognitive differences between Neanderthals and modern humans that might have contributed to Neanderthal extinction.
Sources: en.wikipedia.org
== Occurrence and use == Even though D-amino acids are minimal constituents of living organisms, they occur in a broad range of natural environments such as soils, rivers, lakes, marine systems, snow and ice, aerosols and precipitation. They are produced by several marine microbes, which attain important roles in the carbon and energy cycles in the ocean, and contribute as a carbon source to the oceanic carbon reservoir. D-Amino acid residues occur in cone snails and the venom of the male platypus. They are also abundant components of the peptidoglycan cell walls of bacteria, and D-serine may act as a neurotransmitter in the brain. D-Amino acids are used in racemic crystallography to create centrosymmetric crystals, which, depending on the protein, may allow for easier and more robust protein structure determination. Gramicidin is a polypeptide made up from mixture of D- and L-amino acids. Other compounds containing D-amino acids are tyrocidine and valinomycin. These compounds disrupt bacterial cell walls, particularly in gram-positive bacteria. As of 2011, only 837 D-amino acids were found in the Swiss-Prot database out of a total of 187 million amino acids analysed. Fluorescently labeled D-amino acids, namely FDAAs, have been used for in situ labeling of bacterial peptidoglycan in both gram-positive and gram-negative species.
"In 1990 members of the Bush administration ... cited Security Council resolutions as sufficient support for the President to act militarily against Iraq without congressional authority." A series of UN Security Council resolutions and Arab League resolutions were passed regarding Iraq's invasion of Kuwait. Resolution 678, passed on 29 November 1990, gave Iraq a withdrawal deadline until 15 January 1991 and authorized "all necessary means to uphold and implement Resolution 660", and a diplomatic formulation authorizing the use of force if Iraq failed to comply. To ensure the US received economic backing, James Baker went on an 11-day journey to nine countries in September 1990, which the press dubbed "The Tin Cup Trip". The first stop was Saudi Arabia, which had already granted permission to the US to use its facilities. Baker believed that Saudi Arabia should assume some of the cost of to defend it. When Baker asked King Fahd for $15 billion, the King agreed, with the promise that Baker ask Kuwait for the same amount. The next day, 7 September, Baker did just that, and the emir of Kuwait, displaced in a Sheraton hotel outside Kuwait, agreed. Baker moved to enter talks with Egypt, whose leadership he considered "the moderate voice of the Middle East". President Mubarak was furious with Saddam for his invasion, and that Saddam had assured Mubarak that an invasion was not his intention. Egypt received approximately $7 billion in debt forgiveness for providing support and troops for the US-led intervention.
The cabbage looper (Trichoplusia ni) is a medium-sized moth in the family Noctuidae, a family commonly referred to as owlet moths. Its common name comes from its preferred host plants and distinctive crawling behavior. Cruciferous vegetables, such as cabbage, bok choy, and broccoli, are its main host plant; hence, the reference to cabbage in its common name. The larva is called a looper because it arches its back into a loop when it crawls. While crucifers are preferred, over 160 plants can serve as hosts for the cabbage looper larvae. The adult cabbage looper is a migratory moth that can be found across North America and Eurasia, as far south as Florida and as far north as British Columbia. Its migratory behavior and wide range of host plants contribute to its broad distribution. The cabbage looper larva is a minor vegetable pest, especially for crucifers. While it is not significantly destructive, it is becoming difficult to manage due to its broad distribution and resistance to many insecticides. Numerous methods are being researched in order to control this species.
== Early life == Elizabeth Wettlaufer was born and raised in Zorra Township, a rural community near Woodstock, Ontario. Growing up in a staunchly Baptist household, she went on to earn a bachelor's degree in religious education counseling from London Baptist Bible College after graduating from Huron Park Secondary School in the mid-1980s. Wettlaufer then studied nursing at Conestoga College.
Sources: en.wikipedia.org
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.
The methionine residue at the start of the chain is vulnerable to oxidation, producing a sulfoxide variant. Amide bonds can also hydrolyze, though more slowly under neutral conditions. Cold storage, oxygen exclusion and minimization of freeze-thaw cycles slow both processes but do not stop them.
A purity number on a certificate does not establish that a powder is the same product as a registered nasal medicine. Counter-ion content, residual solvents and peptide-related impurities may differ between the two. Independent verification is the only way to narrow that gap.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.